Navigation Links
Noninvasive current stimulation improves sight in patients with optic nerve damage
Date:10/31/2011

Magdeburg, Germany, October 31, 2011 - It has long been thought that blindness after brain lesions is irreversible and that damage to the optic nerves leads to permanent impairments in everyday activities such as reading, driving, and spatial orientation. A new study published in Elsevier's Brain Stimulation suggests that treating such patients with low levels of non-invasive, repetitive, transorbital alternating current stimulation (rtACS) for 10 days (30-40 min per day) significantly reduces visual impairment and markedly improves vision-related quality of life.

The results of this study showed that treatment with rtACS resulted in an average of 41% shrinkage of the visual field loss. The rtACS-treated patients show significantly improved visual field sizes, which was not seen in patients who received sham treatment. Actively treated patients confirmed that their "general vision" was improved. In the sham-group, visual fields and estimates of subjective visual functioning remained largely unchanged.

"Our findings are important because they show that partial blindness can be reversed. We show for the first time that partial blindness can be reduced by a short-lasting therapeutic procedure using non-invasive electrical current stimulation," states Dr. Bernhard A. Sabel, researcher and senior author of this study

A group of 42 patients with visual impairments following optic nerve damage participated in the study. Patients were randomly assigned to either a control condition with sham stimulation or rtACS given with an alternating current stimulation device (EBS Technologies GmbH, Kleinmachnow, Germany) with electrodes positioned near the eyes. The length of the daily treatment session (both rtACS and sham-treatment) varied between 10 to 20 min for each eye, i.e. max 40 min. The optic nerve lesions were treated long after the early recovery phase (mean lesion age 5.5 yrs). Both patients and the experimenter evaluating the visio
'/>"/>

Contact: Donna Santaromita
d.santaromita@elsevier.com
212-633-3962
Elsevier
Source:Eurekalert

Page: 1 2

Related biology news :

1. Noninvasive wireless near-infrared device provides reliable diagnosis of bladder dysfunction
2. Auxogyn licenses noninvasive embryo assessment technology from Stanford University
3. Noninvasive MR imaging of blood vessel growth in tumors using nanosized contrast agents
4. Cheap, simple, noninvasive blood test may replace invasive diagnostic techniques in early pregnancy
5. Humble garden pea helps Kew scientists develop cool, noninvasive diagnostic test of seed quality
6. Star Trek-like technology offers noninvasive monitor for patients and athletes
7. Frost & Sullivan Recognizes AOptix Technologies for its Pioneering Contribution to Security through Noninvasive Biometrics
8. Elsevier launches Current Opinion in Virology
9. Teeming with life, Pacifics California current likened to Africas Serengeti Plain
10. Glaciations may have larger influence on biodiversity tan current climate
11. Glaciations may have larger influence on biodiversity than current climate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... , May 27, 2015   ... medication safety systems and image documentation solutions ... of comprehensive, technologically-advanced automation solutions, is pleased ... integration. The Codonics® Safe Label System® (SLS), ... in conjunction with the Omnicell Anesthesia Workstation, ...
(Date:5/22/2015)... , May 22, 2015 According ... by Solution (2D, 3D, Thermal, Emotion, Forensic), by Software (Middleware, ... (Government and Utilities, Consumer and Home) - Global Forecast ... grow from $2.77 Billion in 2015 to $6.19 Billion ... Browse 79 market data Tables and   43 ...
(Date:5/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... LLC, a company engaged in biometric identification is an ... portion of the recently awarded TIES (Technical Information Engineering ... Army. 3D-ID LLC has a suite of ... and security agencies. Gino Pereira , ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Facial Recognition Market Worth $6.19 Billion by 2020 2Facial Recognition Market Worth $6.19 Billion by 2020 3NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3
... issue of Nature Genetics, is based on data from ... known genes, but also discovered ten new genes. Altogether ... 3.5 centimeters. The analysis produced some biologically insightful ... the microRNA let-7, which affects the regulation of other ...
... May 2008 Pediatric Academic Societies and Asian Society for ... obesity negatively impacts vascular endothelial function, which relates to ... the U.S. during the past 20 years and obesity ... incidence of obesity in children is also increasing and ...
... has swapped their comfortable offices for one of the ... a challenging field campaign that is seen as the ... mission CryoSat will be as accurate as possible. ... are currently in the middle of CryoSat Validation Experiment ...
Cached Biology News:How body size is regulated 2Study supports reason for concern in childhood and adolescent obesity 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 2Scientists endure Arctic for last campaign prior to CryoSat-2 launch 3
(Date:6/1/2015)... , June 1, 2015 ... the addition of the "Global PDT Machine ...        (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ... 2014 is a professional and in-depth study on ... ,The report provides a basic overview of the ...
(Date:6/1/2015)... Grove, IL (PRWEB) June 01, 2015 ... in developing and manufacturing of chiral stationary phases ... the options for its current and presenting solutions ... Service to its portfolio. This valuable addition to ... fast and effective advantage that can tackle projects ...
(Date:6/1/2015)... 1, 2015  Fennec Pharmaceuticals, Inc. (TSX: FRX, ... results from a poster presented today entitled, "Anti-tumor ... phase III trial of the efficacy of sodium ... cisplatin (Cis) monotherapy for standard risk hepatoblastoma (SR-HB)." ... of Clinical Oncology (ASCO) 2015 Annual Meeting in ...
(Date:6/1/2015)... LANSING, Mich. , June 1, 2015  Neogen Corporation ... the assets of Sterling Test House, a leading commercial food ... and that the acquired laboratory will serve as a base ... . Sterling Test House was ... virtually all of the food safety and water quality testing ...
Breaking Biology Technology:Global PDT Machine Industry Report 2014 2Regis Technologies Offers Chiral Chromatography Service 2Regis Technologies Offers Chiral Chromatography Service 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 2Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 3Fennec Announces Presentation Of Positive Interim Sodium Thiosulfate Phase III Safety Data At The 2015 ASCO Annual Meeting 4Neogen acquires India food safety company 2
... Calif., April 21 /PRNewswire-FirstCall/-- Pharmacyclics,Inc. (Nasdaq: PCYC ... staff,deficiency letter on April 17, 2008 indicating that, ... for Pharmacyclics, common stock has closed,below the minimum ... for continued,inclusion on The Nasdaq Global Market under ...
... Per Share, SAN JOSE, Calif., April 21 ... provider of medical devices,for the minimally invasive treatment of ... quarter ended March 31, 2008., Net revenues for ... compared with $15.6 million for the first quarter of ...
... CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, APRIL 30, ... NBIX ) announced today that the Company will report ... closes on Wednesday,April 30, 2008. Neurocrine will host a ... and provide a Company update Wednesday,afternoon, April 30, 2008 ...
Cached Biology Technology:VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 2VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 3VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 4VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 5VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 6VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales 7Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results 2
... (IC50 = 59.2 M). Formula: ... O 13 MolWeight: ... RT CAS: ... to 100 mM in DMSO IUPAC: ...
POU domain, class 2, transcription factor 2,...
NAP-2 (5C7)...
IKKbeta/IKK-2 Polyclonal Antibody 100 ug affinity purified rabbit polyclonal antibody. Reacts with human. Tested in Western blotting....
Biology Products: